A number of other equities research analysts have also recently weighed in on MTFB. FinnCap reduced their price target on shares of Motif Bio PLC from GBX 125 ($1.66) to GBX 100 ($1.33) and set a buy rating for the company in a research report on Wednesday, June 7th. Beaufort Securities reissued a speculative buy rating and issued a GBX 110 ($1.46) price target on shares of Motif Bio PLC in a research report on Monday, October 2nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of GBX 101.50 ($1.35).
Shares of Motif Bio PLC (MTFB) opened at 42.50 on Thursday. The company’s 50-day moving average price is GBX 33.19 and its 200 day moving average price is GBX 31.42. Motif Bio PLC has a one year low of GBX 21.44 and a one year high of GBX 53.50. The stock’s market capitalization is GBX 111.72 million.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/motif-bio-plc-mtfb-stock-rating-reaffirmed-by-northland-securities/1700173.html.
About Motif Bio PLC
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related companies with our FREE daily email newsletter.